Spots Global Cancer Trial Database for Daptomycin in Treating Neutropenia and Fever in Patients With Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Daptomycin in Treating Neutropenia and Fever in Patients With Cancer

Official Title: Phase II Open Label Pilot Trial of Empiric Daptomycin Treatment for Oncology Patients With Neutropenic Fever

Study ID: NCT00335478

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

Daptomycin

Study Description

Brief Summary: RATIONALE: Antibiotics, such as daptomycin, may control neutropenia, fever, and infection in patients with cancer. PURPOSE: This phase II trial is studying how well daptomycin works in treating neutropenia and fever in patients with cancer.

Detailed Description: OBJECTIVES: Primary * Assess the response rate to therapy within 72 hours of starting daptomycin in cancer patients with neutropenic fever. Secondary * Assess the percentage of bacterial cures in patients with documented gram-positive bacterial infections. * Assess time to afebrile state. * Assess the pharmacokinetic data of daptomycin in neutropenic patients. * Document the incidence of breakthrough infections that require a change of therapy or additional agents to clear. * Assess the tolerability of daptomycin in neutropenic patients. * Assess and document adverse events and toxicity due to daptomycin. OUTLINE: This is an open-label, pilot study. Patients first receive standard treatment for gram-negative bacteria for 72 hours. If the patient is still febrile at 72 hours, daptomycin is administered. Patients receive daptomycin IV over 30 minutes once daily. Patients who are afebrile, not neutropenic (absolute neutrophil count \[ANC\] \> 500/mm³), and have no signs of infection after 72 hours of therapy may discontinue daptomycin. Patients who are afebrile and neutropenic (ANC \< 500/mm³) after 72 hours of therapy continue to receive daptomycin until absolute neutrophil count (ANC) \> 500/mm³ for 2 consecutive days. Patients who are febrile with or without continued neutropenia (ANC \< 500/mm³) after 72 hours of therapy continue to receive daptomycin for up to 10-14 days in the absence of unacceptable toxicity. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.